SCHEMBL7568567

SCHEMBL7568567

O=C1c2ccccc2C(=O)c2c1oc1c3ccccc3c3ccccc3c21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 6/20 0.56
▸ NTRK1 P04629 1/20 0.50
▸ PLK3 Q9H4B4 1/20 0.50
▸ PDGFRB P09619 5/20 0.47
▸ FGFR1 P11362 5/20 0.47
▸ KDR P35968 5/20 0.47
▸ MAPT P10636 6/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ HTT P42858 4/20 0.43
▸ LMNA P02545 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ APAF1 O14727 3/20 0.43
▸ MITF O75030 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ADORA2A P29274 2/20 0.41
▸ MAOA P21397 2/20 0.41
▸ FGR P09769 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ CSNK1A1 P48729 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7572057 0.74 NTRK1 (0.45) EGFRNTRK1PLK3PDGFRBFGFR1
SCHEMBL9101234 0.73 GRK6 (0.46) EGFRNTRK1PLK3PDGFRBFGFR1
SCHEMBL7575236 0.73 NTRK1 (0.55) EGFRNTRK1PLK3MAPTKMT2A
SCHEMBL2681675 0.73 ABCG2 (0.49) NTRK1PLK3MAPTALDH1A1HTT
SCHEMBL7572043 0.73 NTRK1 (0.51) EGFRNTRK1PLK3KDRMAPT
SCHEMBL7571387 0.73 EGFR (0.45) EGFRNTRK1PLK3PDGFRBFGFR1
SCHEMBL30704422 0.73 NTRK1 (0.74) NTRK1PLK3MAPTALDH1A1HTT
SCHEMBL11768754 0.73 NTRK1 (0.74) NTRK1PLK3MAPTALDH1A1HTT
SCHEMBL7570512 0.71 MAPT (0.53) EGFRNTRK1PLK3PDGFRBFGFR1
SCHEMBL31238201 0.70 CSF1R (0.48) EGFRPLK3MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020182232-A9 Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof L'OREAL S.A. (FR) 2002-12-05 — — US claimed
US-20020012683-A1 Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof HENRION JEAN-CHRISTOPHE (FR) 2002-01-31 — — US claimed
US-20020182232-A9 Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof L'OREAL S.A. (FR) 2002-12-05 — — US disclosed
US-20020012683-A1 Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof HENRION JEAN-CHRISTOPHE (FR) 2002-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020012683-A1 Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof CYP1B1, NDUFA2, TYR EGFR 4276/4885NTRK1 4814/4885PLK3 1152/4885
US-20020182232-A9 Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof TYR, SDHA, NDUFA2 EGFR 4183/4885NTRK1 4797/4885PLK3 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback